Freenome Will Present Updated Cancer Test Data
The company will unveil clinical results for its improved colorectal cancer screening assay at a conference in Nashville.
Updated on Oct. 11, 2026 in Cancer
Live Poll
Do you trust non-invasive blood tests as a reliable alternative to traditional cancer screening methods?
Freenome is set to present new validation data for its updated SimpleScreen CRC test on October 14, 2026. The presentation will highlight improved sensitivity metrics for the colorectal cancer screening assay.
Why it matters
The company is utilizing an iterative methodology strategy to boost the accuracy of its screening tool following the commercial launch of its first-generation test earlier this year.
The updated test demonstrates 80.4% sensitivity for colorectal cancer detection and 90% specificity for no findings on colonoscopy, based on results adjusted to U.S. Census age and sex distributions.
The players
Freenome
Freenome is a Brisbane, California-based biotechnology company focused on developing blood-based tests for early cancer detection.
Dr. Aasma Shaukat
Dr. Aasma Shaukat is the medical expert scheduled to present the updated clinical validation results at the ACG 2026 meeting.
The details
Freenome conducted a clinical study to assess improvements to its assay and detection algorithms. The company will showcase these refined performance metrics at the American College of Gastroenterology (ACG) meeting.
Timeline
June 2, 2025: The original PREEMPT CRC study was published in JAMA.
July 2026: The FDA granted approval for the first-generation SimpleScreen CRC test.
September 2026: The test was launched commercially across the United States.
October 11, 2026: Freenome announced the upcoming presentation of the new data.
October 14, 2026: Dr. Aasma Shaukat will present the updated results at the ACG meeting.
The Big Picture
This development follows the performance benchmarks established by the PREEMPT CRC study. The new findings represent an iterative evolution of the diagnostic framework set by that initial research.
This update may provide clinicians with more precise screening options for detecting advanced precancerous lesions. Patients should consult their healthcare providers to determine if newer diagnostic assays are appropriate for their specific screening needs.
The takeaway
Advancements in blood-based screening tests are designed to increase detection rates for colorectal cancer and precancerous lesions. Readers should continue to follow recommended screening schedules as guided by their medical providers.
What happens next
Dr. Aasma Shaukat is scheduled to present the late-breaking validation data on October 14, 2026, at the ACG meeting in Nashville.
Further reading
Learn more about advancements in Cancer diagnostics and screening methods.
More information
For more information on the testing technology, visit the Freenome company and product information.
Live Poll
Do you trust non-invasive blood tests as a reliable alternative to traditional cancer screening methods?
